PepGene is an immuno-oncology company using novel computational algorithms and drug delivery technology to create personalized, neoantigen-based therapeutics. Motivated by a wide range of unmet needs in cancer treatment, PepGene combines AI algorithms with novel neoantigen sources and novel vaccine delivery system to create highly-personalized, low-risk cancer vaccines that can activate the human immune system to efficiently eradicate cancer cells while minimizing the potential of side effects. By using cutting-edge technologies, PepGene is dedicated to creating neoantigen-based therapeutics that can significantly increase the specificity of cancer immunotherapy treatment and improve the life quality of cancer patients.
Neoantigens are mutant proteins that come from non-self genomic alterations. In the context of cancer hallmarks, neoantigens occur only on the surface of cancerous cells and can direct the T cell immune response and drive cancer cell killing. Neoantigens are tumor-specific, which makes it a compelling therapeutic strategy to direct the human immune system to target neoantigen-tagged cancer cells without affecting normal cells.
PepGene combines its unique advantages in both computational and experimental platforms to develop personalized cancer vaccines as a valid and low-risk treatment feasible to a wide range of cancer patients:
Novel Neoantigen Sources
of neoantigen sources,
originate from both coding
regions and non-coding
AI Algorithm Engine
Novel AI algorithm
to improve the neoantigen prediction by in-house generated data
Novel Delivery System
delivery technology that enhances the half-life time and the immune-activation potency of vaccine.